Immune responses to ISCOM® formulations in animal and primate models

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2661-2665

  Sjölander, Anders ^a   Drane, Debbie ^a   Maraskovsky, Eugene ^b   Scheerlinck, Jean Pierre ^c   Suhrbier, Andreas ^d   Tennent, Jan ^e   Pearse, Martin ^a  

^a CSL LIMITED   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e CSIRO   (Australia)

Author keywords

Immune responses; ISCOM ; T cell

Indexed keywords

ANTIBODY; ANTIGEN; CHOLESTEROL; IMMUNOSTIMULATING AGENT; ISCOM; ISCOMATRIX; ISCOPREP 703; PHOSPHOLIPID; SAPONIN;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG FORMULATION; DRUG MECHANISM; HUMAN; IMMUNOSTIMULATION; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; ISCOMS; MICE; MODELS, ANIMAL; PRIMATES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES;

EID: 0035925595     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00497-7     Document Type: Conference Paper

References (29)

1. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
2. ISCOMs and other saponin based adjuvants
3. Immunostimulating complexes. Clinical potential in vaccine development
4. ISCOMs: An adjuvant with multiple functions
5. ™ adjuvant - A promising adjuvant for influenza virus vaccines
6. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
7. A study of the isolation and characterization of the saponin Quil A
8. Classical and new approaches to adjuvant use in domestic food animals
9. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex
10. Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (Iscoms): Chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems
11. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix
12. Preparation and use of adjuvants
13. ™ vaccines
14. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses
15. Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-γ
16. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action
17. Induction of lymphocyte recruitment in the absence of a detectable immune response
18. Monocyte and iscom enhancement of cell-mediated response to cytomegalovirus
19. Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and iscom vaccines
20. Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp 125
21. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance
22. The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection
23. β-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
24. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 candidates
25. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5)
26. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into iscoms primes cytotoxic T cell responses directed against EBV lymphoblastoid cell lines
27. Prospects for the development of new vaccine adjuvants